Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  Google Scholar 

  2. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943–2964.

    Article  CAS  Google Scholar 

  3. Senent L, Arenillas L, Luno E, Ruiz JC, Sanz G, Florensa L . Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 2013; 98: 568–575.

    Article  Google Scholar 

  4. Nybakken GE, Bagg A . The genetic basis and expanding role of molecular analysis in the diagnosis, prognosis, and therapeutic design for myelodysplastic syndromes. J Mol Diagn 2014; 16: 145–158.

    Article  CAS  Google Scholar 

  5. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247.

    Article  CAS  Google Scholar 

  6. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616–3627.

    Article  CAS  Google Scholar 

  7. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275–1282.

    Article  CAS  Google Scholar 

  8. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496–2506.

    Article  CAS  Google Scholar 

  9. Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S et al. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA 2015; 314: 811–822.

    Article  CAS  Google Scholar 

  10. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126: 9–16.

    Article  CAS  Google Scholar 

  11. Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015; 126: 2355–2361.

    Article  CAS  Google Scholar 

  12. Cargo CA, Rowbotham N, Evans PA, Barrans SL, Bowen DT, Crouch S et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 2015; 126: 2362–2365.

    Article  CAS  Google Scholar 

  13. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477–2487.

    Article  Google Scholar 

  14. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488–2498.

    Article  Google Scholar 

Download references

Acknowledgements

Support for this study was provided by the Washington University Hematology Scholars K12 award (5-K12-HL087107-05 to EJD), Washington University Institute of Clinical and Translational Sciences Grant UL1TR000448 from the National Center for Advancing Translational Sciences (NCATS) (EJD), a SPORE in Leukemia (P50CA171063 to EJD and MJW), P01 CA101937 (TJL) and U54 HG003079 (RKW) from the National Institutes of Health, and a Leukemia and Lymphoma Society Scholar Award (MJW). Technical assistance was provided by the Tissue Procurement Core supported by a National Cancer Institute Cancer Center Support Grant (P30CA91842).

Protection of Human Subjects

All patients sequenced as part of this study were fully consented for sequencing studies.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E J Duncavage.

Ethics declarations

Competing interests

EJD is a technical consultant for PierianDx, Cofactor Genomics and Molecular Health, none of which were involved in this study.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duncavage, E., O'Brien, J., Vij, K. et al. Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome. Leukemia 30, 2422–2426 (2016). https://doi.org/10.1038/leu.2016.247

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2016.247

Search

Quick links